INFI - Infinity Pharmaceuticals GAAP EPS of -$0.14 in-line revenue of $0.65M beats by $0.39M

Infinity Pharmaceuticals press release (NASDAQ:INFI): Q1 GAAP EPS of -$0.14 in-line. Revenue of $0.65M (+38.3% Y/Y) beats by $0.39M. 2022 Guidance: Net Loss: Infinity expects net loss for 2022 to range from $45 million to $55 million. Cash and Investments: Infinity expects to end 2022 with a year-end cash, cash equivalents and available for sale securities balance ranging from $25 million to $35 million. Infinity’s financial guidance does not include additional funding or business development activities Shares +5%.

For further details see:

Infinity Pharmaceuticals GAAP EPS of -$0.14 in-line, revenue of $0.65M beats by $0.39M